ICB Biotechnology Investments Ltd.

Silver Castle, a global asset management and hedge ​fund investment house for digital currencies, has reverse merged into ICB in a share swap deal.

Together with CIB, ICB's major shareholder, ICB have formed joint ventures (JV) in China with most of its invested companies, opening the door for them to the huge Chinese market and to new investors.

ICB (previously named BSP) has been in the biotech industry for many years. In 2017, Mr. Huang Qingxi, a Chinese investor, took control of the company, and the board of directors shifted priority to become an investment company in the biomedical field. ​ICB Biotechnology Investments Ltd. (ICB) shifted business strategy in 2018 to become a leading high-tech healthcare investor in Israeli medical companies that directly provides funding to pave the way for Israeli companies into China, the biggest emerging market in the world. In Early 2019 ICB transferred BSP's previous technological activity in the field of diagnosis and monitoring of Ischemic Heart Disease to its subsidiary BSP Medical.